# CJC-1295 Ipamorelin: A Field Notebook on the GHRH + GHRP Pairing

> CJC-1295 Ipamorelin pairs a long-acting GHRH analogue with a selective growth-hormone-releasing peptide. A plain-English digest of what the GH-axis literature records for each half, cited.

A field notebook on the two-peptide research pairing: each half read against its own studies, the supra-additive growth-hormone pulse traced to the mechanism, and every number cited.

## Start here

CJC-1295 Ipamorelin is not one drug. It is a research pairing of two separate peptides that both nudge the body to release more of its own growth hormone (GH) — the hormone that, among other jobs, helps tissue repair and deep sleep. CJC-1295 is a long-acting copy of GHRH (the brain's natural "make growth hormone" signal). Ipamorelin is a small peptide that hits a second, different switch on the same pituitary cells (the ghrelin receptor). Because the two switches are independent, pressing both at once produces a bigger GH pulse than either alone [3][4].

Neither peptide is approved by the FDA, and the fixed two-peptide blend has never been tested in a controlled human trial. Everything here is read from the studies of each compound on its own, plus the general research on combining a GHRH with a GH-releasing peptide. What people report — including the downsides like water retention and post-injection flushing — is on [CJC-1295 Ipamorelin effects](/effects).

## What the literature records for each half of the stack

The headline number sits with the long-acting half. In healthy adults aged 21 to 61, a single subcutaneous dose of CJC-1295 (with DAC) raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for nine to eleven days; with repeated dosing, IGF-1 stayed above baseline for up to 28 days [1]. IGF-1 (insulin-like growth factor 1, the liver-made messenger that carries out much of GH's work) is the downstream readout that this stack is built to move.

The other half earns its place by being clean. Ipamorelin was the first *selective* GH secretagogue: unlike the older peptides GHRP-6 and GHRP-2, it did not raise the stress hormones ACTH or cortisol above resting-stimulated levels even at doses more than 200 times the amount needed for GH release, while still matching GHRP-6's GH output in swine [2]. That selectivity — a strong GH pulse without dragging the stress axis along — is the reason ipamorelin is the GH-releasing peptide most often paired with CJC-1295.

## Why two peptides instead of one

The pairing rests on a 1990 finding in eighteen normal men: submaximal doses of a GH-releasing peptide (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) released GH *synergistically* — supra-additively, meaning the combined pulse was larger than the two effects added together — because the two arms act through independent mechanisms [3]. A 2002 cell study put a number on the mechanism: co-activating the cloned GHRH and ghrelin receptors in transfected cells produced roughly twice the cAMP signal of the GHRH receptor alone [4].

So the design logic is honest and old. What is *not* established is that this exact, fixed pre-mix behaves like those study pairs — those experiments used related peptides and controlled intravenous doses, not the CJC-1295 + ipamorelin combination at research-use subcutaneous doses. The pairing is a reasonable read of the synergy literature, not a tested product.

## Two timescales: DAC versus no-DAC

The single most useful distinction to carry through everything below is the difference between the two forms of the CJC-1295 half. The "with DAC" form carries a Drug Affinity Complex — a chemical tag that covalently binds Cys34 of serum albumin (a long-lived blood protein), parking the peptide in circulation for a multi-day half-life of roughly six to eight days in humans [1][5]. The "no-DAC" form, commonly called [mod grf 1-29](/mod-grf-1-29), drops that tag and instead gives a short, pulsatile GHRH signal on the order of thirty minutes, like native GHRH. Same receptor, very different exposure. The detailed contrast lives on the [cjc 1295 dac](/cjc-1295-dac) page.

Neither CJC-1295 nor ipamorelin is FDA-approved; both are sold only as research chemicals, and both are prohibited at all times for athletes under WADA Section S2 (peptide hormones and GH secretagogues).

---

A darkroom field notebook on the CJC-1295 + ipamorelin pairing — each peptide developed against its own studies, the supra-additive growth-hormone pulse traced and cited, and the never-trialed blend left as the one honest unexposed plate; no clinic behind the safelight and nothing here dosed, compounded, prescribed, or sold.